Navigation Links
Karolinska Development Invests in EvoStem Finland Oy
Date:1/12/2009

STOCKHOLM, January 12 /PRNewswire/ -- Sweden The Swedish investment company Karolinska Development AB has made a significant investment in EvoStem Finland Oy that develops stem cell and other tissue engineering based treatments for veterinary and human use.

In 2007 EvoStem Finland Oy introduced its first product TendoStem(R), which is a stem cell based treatment service for tendon and ligament injuries in horses. TendoStem(R) is currently on the market in Scandinavia.

"With this investment, we will speed up our international growth and product development projects," says Dr. Minna Leppanen, the CEO of EvoStem Finland Oy.

"We are targeting global markets, and currently we are engaged in negotiations for expansion of our market area. The investment of Karolinska Development AB and its strong, long-time commitment gives us a solid ground for a long-term development of our company," Leppanen continues.

"EvoStem has demonstrated that stem cell therapy for regenerative medicine is ready for the market. With our investment in EvoStem we strengthen our presence in the cell therapy area where we expect strong growth and medical progress," comments Investment Manager Hans-Peter Ekre, Karolinska Development AB.

About EvoStem Finland Oy

EvoStem Finland Oy develops, produces and markets stem cell based treatment methods for animals and man. The company's current focus is on orthopaedic and sports medicine applications. EvoStem Finland Oy was founded in 2005 as a spin-off of Tampere University Institute of Regenerative Medicine Regea and is based in Tampere, Finland.

http://www.evostem.com

About Karolinska Development

Managing one of the largest portfolios of life science research companies in Europe, Karolinska Development is a Swedish investment company using a unique, highly cost effective model to commercialize internationally renowned life science innovations. Professionals in business development and management, supported by a network of experienced technical specialists, ensure fast and efficient development. This enables Karolinska Development to rapidly build value in high risk opportunities, through long term lead investor position from seed stage; developing the medical products of the future. Karolinska Development's office is located at the Karolinska Institutet Science Park, Solna/Stockholm Sweden.

   http://www.karolinskadevelopment.com

    For more information, please contact:
    CEO Minna Leppanen, EvoStem Finland Oy,
    mobile +358-40-504-4423,
    minna.leppanen(at)evostem.com

    Investment Manager Hans-Peter Ekre, Karolinska Development AB,
    mobile +46-70-533-67-47,
    hans-peter.ekre(at)karolinskadevelopment.com


'/>"/>
SOURCE Karolinska Development and EvoStem
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Dr. Henry Barnett becomes first person outside Europe to receive Karolinska Stroke Award
2. The Feinstein to collaborate with Swedens Karolinska Institute
3. 3 new honorary doctors at Karolinska Institutet
4. Karolinska Institutets Pedersen to receive GSAs 2007 Distinguished Career Award
5. Reduce Risk, Achieve Compliance and Accelerate Time to Market with hiQual and Hiemstra Product Development
6. Blog Launched to Discuss Developments in Hydrophilic Coatings for Medical Devices
7. New Markets Development Program Brings Renovations, Equipment to Bastrop, Louisiana Hospital
8. New drug development still takes 8 years despite faster FDA review, according to Tufts CSDD
9. The Leukemia & Lymphoma Society and The University of Kansas Cancer Center Announce Innovative Partnership to Accelerate Drug Development
10. BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
11. New Zealand Waynes New Resources Development Co., Ltd. Completes Reverse Merger to Go Public in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... May 23, 2016 , ... While new U.S. opioid ... physicians are not legally required to follow them. In the absence of federal ... Novus Medical Detox Center , a leading Florida-based drug treatment facility, strongly ...
(Date:5/23/2016)... ... ... the upcoming airing of Innovations with Ed Begley, Jr., ... 4:00pET via Fox Business. , The show will explore ... safely and rapidly develop cures for mosquito-borne, emerging infectious ...
(Date:5/23/2016)... , ... May 23, 2016 ... ... Size for Verification and Validation:, Tools to Safely Speed Your Device to ... http://www.fdanews.com/bestdevicesamplesizevv                  , Today's FDA inspectors focus like lasers on device ...
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... ... the action analytics leader as Chief Medical Officer. Dr. O’Connor’s deep expertise in ... product development and client services teams who deliver best-in-class solutions and transformative technologies ...
(Date:5/23/2016)... Valley, California (PRWEB) , ... May 23, 2016 ... ... clinical communications and solutions for healthcare providers announced today that AGNITY MobileCare™ Platform ... and health collaboration applications as a part of its M-Health Solution. Tech Mahindra ...
Breaking Medicine News(10 mins):
(Date:5/19/2016)... Israel , May 19, 2016 ... the "Company"), an emerging global ophthalmic company focused on ... candidates which address ophthalmic conditions, announced today that it ... Italy ) for the manufacturing, distribution, marketing ... for the treatment of dry eye syndrome (DES) and ...
(Date:5/19/2016)... May 19, 2016 A ... World Biopsy Devices Market Opportunities and Forecasts, 2014 ... market generated $1,621 million in 2015. The MRI-guided ... and is expected to maintain this trend over ... http://photos.prnewswire.com/prnh/20140911/647229 ) , To know ...
(Date:5/19/2016)... BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced ... of multiple cancer and hematological indications, will be presented ... titled " Clinical response in relapsed/refractory AML patients correlates ... a potent CXCR4 antagonist; results of a Phase 2a ... the European Hematology Association 21st Congress, to be held ...
Breaking Medicine Technology: